Recursion Pharmaceuticals Documenti
Documenti
100
Ticker
RXRX
ISIN
US75629V1044
Recursion Pharmaceuticals SEC Filings
Recursion Pharmaceuticals Documenti 2026
Questa pagina contiene tutti i documenti ufficiali e i filing SEC dell'azione Recursion Pharmaceuticals (RXRX, ISIN: US75629V1044). Sono incluse le relazioni annuali (Form 10-K), le relazioni trimestrali (Form 10-Q) e le transazioni degli insider (Form 4). Attualmente sono disponibili 100 documenti. I dati vengono aggiornati regolarmente per offrire agli investitori una panoramica completa dei depositi regolamentari di Recursion Pharmaceuticals.
Recursion Pharmaceuticals Analisi delle Azioni
Recursion Pharmaceuticals Recursion Pharmaceuticals Inc is a biotechnology company based in Salt Lake City, Utah, operating in the Health Care sector. The company went public via an IPO on April 16, 2021. It employs approximately 600 people. Recursion Pharmaceuticals utilizes automation, artificial intelligence, and machine learning technologies to discover novel medicines. The company's platform, referred to as the Recursion Operating System (OS), integrates physical and digital components to map and navigate biological and chemical relationships. The company's approach involves iterative loops between wet lab biology and chemistry data, organized into cycles with computational tools to translate digital hypotheses into validated insights. Recursion Pharmaceuticals has clinical programs including REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is described as an orally bioavailable, superoxide scavenger small molecule being developed for the treatment of cerebral cavernous malformations. The company's website is www.recursion.com. It is listed under the ticker symbol RXRX with ISIN US75629V1044. The company's headquarters are located in Salt Lake City, Utah.